Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.37 |
| ▸ | F7 | P08709 | 12/20 | 0.35 |
| ▸ | F3 | P13726 | 12/20 | 0.35 |
| ▸ | F2 | P00734 | 6/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 7/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.35 |
| ▸ | BCL2 | P10415 | 1/20 | 0.34 |
| ▸ | LSS | P48449 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3859147 | 0.96 | LSS (0.37) | NR1H2F7F3F2SCN9A | |
| SCHEMBL3863253 | 0.90 | F7 (0.40) | NR1H2F7F3F2F10 | |
| SCHEMBL3863423 | 0.86 | F7 (0.41) | NR1H2F7F3F2F10 | |
| SCHEMBL13084144 | 0.85 | F7 (0.48) | F7F3F2F10PRSS1 | |
| SCHEMBL3862749 | 0.84 | PPARG (0.38) | F7F3F2F10F11 | |
| SCHEMBL3867525 | 0.83 | F7 (0.37) | F7F3F2F10F11 | |
| SCHEMBL3959189 | 0.83 | PPARG (0.37) | F7F3F2F10F11 | |
| SCHEMBL3858807 | 0.79 | F7 (0.36) | F7F3F2F10PRSS1 | |
| SCHEMBL3859056 | 0.79 | F7 (0.33) | F7F3F2F10F11 | |
| SCHEMBL3857276 | 0.78 | F7 (0.37) | F7F3F2F10F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971582-B1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL MYERS SQUIBB CO (US) | 2012-10-10 | — | — | EP | disclosed |
| US-20090281139-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-12 | — | — | US | disclosed |
| US-20090281139-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-12 | — | — | US | disclosed |
| US-7592331-B2 | Macrocyclic factor VIIa inhibitors useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592331-B2 | Macrocyclic factor VIIa inhibitors useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-22 | — | — | US | disclosed |
| US-20070208054-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-06 | — | — | US | disclosed |
| US-20070208054-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281139-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | F12, F7, F2 | NR1H2 1551/4885F7 2/4885F3 10/4885 |
| US-20070208054-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | F12, F7, F2 | NR1H2 1551/4885F7 2/4885F3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.